Nifty
Sensex
:
:
10382.70
33819.50
-14.75 (-0.14%)
-25.36 (-0.07%)

Pharmaceuticals & Drugs

Rating :
64/99   (View)

BSE: 532523 | NSE: BIOCON

619.75
40.10 (6.92%)
22-Feb-2018 | 3:53PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 581.00
  • 629.00
  • 576.00
  • 579.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 14561999
  • 90247.99
  • 657.50
  • 295.03

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 34,902.00
  • 94.46
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 36,160.20
  • 0.17%
  • 6.92

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 2.92%
  • 12.53%
  • FII
  • DII
  • Others
  • 1.36%
  • 2.46%
  • 20.06%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Net Sales
1,057.90
1,037.60
1.96%
968.60
945.80
2.41%
933.70
982.40
-4.96%
931.10
978.80
-4.87%
Expenses
836.20
761.50
9.81%
786.30
705.80
11.41%
741.60
719.30
3.10%
743.60
765.70
-2.89%
EBITDA
221.70
276.10
-19.70%
182.30
240.00
-24.04%
192.10
263.10
-26.99%
187.50
213.10
-12.01%
EBIDTM
20.96%
26.44%
18.82%
25.15%
20.57%
26.78%
20.14%
21.77%
Other Income
33.90
47.40
-28.48%
50.80
38.40
32.29%
54.00
40.90
32.03%
43.20
24.70
74.90%
Interest
14.70
8.80
67.05%
13.80
6.50
112.31%
16.10
5.70
182.46%
5.00
1.40
257.14%
Depreciation
97.40
70.30
38.55%
93.60
68.30
37.04%
98.80
66.10
49.47%
72.50
62.80
15.45%
PBT
143.50
244.40
-41.28%
125.70
203.60
-38.26%
131.20
232.20
-43.50%
153.20
442.00
-65.34%
Tax
36.10
54.40
-33.64%
42.50
41.70
1.92%
37.60
55.20
-31.88%
10.30
58.20
-82.30%
PAT
107.40
190.00
-43.47%
83.20
161.90
-48.61%
93.60
177.00
-47.12%
142.90
383.80
-62.77%
PATM
10.15%
18.19%
8.59%
16.97%
10.02%
18.02%
15.35%
39.21%
EPS
1.53
2.86
-46.50%
1.15
2.44
-52.87%
1.36
2.78
-51.08%
2.13
6.01
-64.56%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
3,891.30
3,891.10
3,347.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
1,608.67
1,053.79
Net Sales Growth
-1.35%
16.24%
8.34%
7.39%
15.77%
19.11%
15.53%
-23.73%
47.19%
52.66%
 
Cost Of Goods Sold
1,503.50
1,446.60
1,290.40
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
838.42
434.62
Gross Profit
2,387.80
2,444.50
2,057.00
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
770.25
619.17
GP Margin
61.36%
62.82%
61.45%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
47.88%
58.76%
Total Expenditure
3,107.70
2,911.60
2,579.60
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
1,285.31
757.67
Power & Fuel Cost
-
156.40
184.70
176.70
162.40
142.60
97.20
82.00
67.63
69.33
76.56
% Of Sales
-
4.02%
5.52%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
4.31%
7.27%
Employee Cost
-
747.00
610.10
533.40
466.30
389.40
307.60
238.80
242.76
179.18
110.68
% Of Sales
-
19.20%
18.23%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
11.14%
10.50%
Manufacturing Exp.
-
376.20
320.90
81.20
62.90
95.20
113.20
81.60
68.63
66.01
47.71
% Of Sales
-
9.67%
9.59%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
4.10%
4.53%
General & Admin Exp.
-
21.70
42.60
165.70
131.80
122.20
93.20
82.40
79.09
56.15
38.71
% Of Sales
-
0.56%
1.27%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
3.49%
3.67%
Selling & Distn. Exp.
-
107.40
100.80
108.70
118.90
99.60
89.40
62.40
56.49
47.67
32.53
% Of Sales
-
2.76%
3.01%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
2.96%
3.09%
Miscellaneous Exp.
-
56.30
30.10
72.70
61.80
52.90
256.70
940.80
44.19
28.55
32.53
% Of Sales
-
1.45%
0.90%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
1.77%
1.60%
EBITDA
783.60
979.50
767.80
695.80
687.10
539.00
277.20
-407.40
471.49
323.36
296.12
EBITDA Margin
20.14%
25.17%
22.94%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
20.10%
28.10%
Other Income
181.90
157.10
79.20
53.10
55.90
56.70
309.40
1,035.50
37.02
64.55
38.88
Interest
49.60
26.00
29.30
8.90
1.70
8.10
12.40
24.30
16.89
17.66
10.18
Depreciation
362.30
277.20
248.70
221.00
203.60
179.30
175.80
156.70
140.14
110.25
93.92
PBT
553.60
833.40
569.00
519.00
537.70
408.30
398.40
447.10
351.47
260.00
230.91
Tax
126.50
161.60
142.20
95.70
106.90
97.50
55.90
72.10
48.67
11.84
12.89
Tax Rate
22.85%
19.39%
19.49%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
10.50%
2.74%
PAT
427.10
595.80
528.70
497.40
413.80
508.90
341.60
367.50
293.25
93.84
463.91
PAT before Minority Interest
347.80
671.80
587.40
528.40
430.80
512.70
342.50
375.00
302.81
100.97
457.39
Minority Interest
-79.30
-76.00
-58.70
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
-7.13
6.52
PAT Margin
10.98%
15.31%
15.79%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
5.83%
44.02%
PAT Growth
-53.20%
12.69%
6.29%
20.20%
-18.69%
48.98%
-7.05%
25.32%
212.50%
-79.77%
 
Unadjusted EPS
6.17
31.18
28.04
24.87
21.09
25.99
17.27
18.79
15.08
4.83
46.39

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
4,837.70
4,033.80
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
1,510.74
1,484.15
Share Capital
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
50.00
Total Reserves
4,737.70
3,933.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
1,369.32
1,397.80
Non-Current Liabilities
2,304.60
2,421.30
1,377.90
1,262.00
666.30
645.20
455.50
564.44
570.54
301.55
Secured Loans
2,104.30
2,061.00
758.20
580.40
124.00
9.30
0.00
331.50
395.73
135.04
Unsecured Loans
3.90
11.40
11.40
25.80
40.00
60.50
65.80
182.11
128.18
120.01
Long Term Provisions
36.00
29.90
15.00
7.80
4.00
0.00
1.00
0.00
0.00
0.00
Current Liabilities
1,678.30
1,665.70
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
438.50
301.42
Trade Payables
739.70
609.80
429.30
347.20
345.50
347.80
296.50
230.86
208.55
172.38
Other Current Liabilities
698.20
527.10
706.20
612.30
313.10
269.20
375.90
260.05
148.42
57.64
Short Term Borrowings
97.20
394.90
261.00
243.50
84.80
187.30
247.40
0.00
0.00
0.00
Short Term Provisions
143.20
133.90
158.20
176.60
246.50
211.50
140.80
90.83
81.53
71.40
Total Liabilities
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.80
Net Block
3,625.10
1,748.30
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
1,211.56
931.28
Gross Block
5,436.10
3,403.60
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
1,581.70
1,182.39
Accumulated Depreciation
1,811.00
1,655.30
1,404.30
1,176.50
970.60
795.70
649.60
499.20
370.14
251.11
Non Current Assets
5,149.00
4,415.70
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
1,422.68
1,101.10
Capital Work in Progress
839.20
2,239.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
172.02
138.21
Non Current Investment
188.80
26.80
0.00
64.50
64.50
64.20
60.90
47.16
39.10
31.60
Long Term Loans & Adv.
428.90
350.10
336.90
252.00
241.60
181.00
140.20
0.00
0.00
0.00
Other Non Current Assets
67.00
51.00
169.60
64.50
47.20
32.30
0.00
0.00
0.00
0.00
Current Assets
4,047.70
3,970.90
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
1,121.87
978.71
Current Investments
1,065.00
874.70
230.30
700.40
522.10
492.10
399.50
383.42
328.52
443.16
Inventories
635.30
542.40
452.70
376.60
398.40
378.30
413.70
371.64
319.18
178.98
Sundry Debtors
883.20
714.50
770.50
599.80
509.70
491.70
495.80
446.13
366.68
259.13
Cash & Bank
1,044.30
1,538.60
937.50
804.40
672.90
523.30
441.50
139.93
11.81
9.62
Other Current Assets
419.90
73.60
95.80
75.80
136.90
114.30
56.70
136.10
95.67
87.82
Short Term Loans & Adv.
267.80
227.10
75.80
81.80
81.40
37.10
20.20
120.28
95.05
82.76
Net Current Assets
2,369.40
2,305.20
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
683.37
677.28
Total Assets
9,196.70
8,386.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
526.40
210.70
560.70
471.20
564.10
798.50
443.81
95.10
317.91
154.76
PBT
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
104.36
538.66
211.00
Adjustment
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
135.89
-213.83
82.18
Changes in Working Capital
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
-128.21
17.34
-125.19
Cash after chg. in Working capital
773.20
344.10
709.40
565.20
638.00
879.80
476.60
112.04
342.18
167.99
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
-16.94
-24.27
-13.24
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
-232.19
-340.15
-191.17
Net Fixed Assets
-216.90
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
-84.56
-53.65
-118.55
Net Investments
-3,688.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
130.57
-430.24
92.04
Others
2,951.00
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
-278.20
143.74
-164.66
Cash from Financing Activity
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
136.93
23.22
43.09
Net Cash Inflow / Outflow
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
-0.16
0.99
6.68
Opening Cash & Equivalents
462.60
557.00
474.00
369.00
359.00
139.90
11.81
9.62
8.63
1.95
Closing Cash & Equivalent
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10
11.81
9.62
8.63

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
80.61
67.22
53.86
48.42
43.18
36.31
32.49
28.25
24.47
24.11
ROA
7.64%
7.96%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
4.37%
25.03%
ROE
15.15%
16.17%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
6.93%
36.76%
ROCE
12.59%
13.93%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
6.92%
32.11%
Fixed Asset Turnover
0.89
1.05
1.09
1.12
1.11
1.06
0.97
1.42
1.19
0.96
Receivable days
74.35
80.16
80.09
69.48
72.22
84.37
93.20
60.98
69.27
95.54
Inventory Days
54.81
53.71
48.47
48.54
56.01
67.67
77.71
51.83
55.14
57.48
Payable days
79.07
68.27
58.15
55.73
65.24
70.25
70.62
41.52
51.80
83.01
Cash Conversion Cycle
50.09
65.60
70.42
62.29
62.99
81.79
100.29
71.30
72.61
70.02
Total Debt/Equity
0.48
0.61
0.35
0.30
0.10
0.12
0.17
0.30
0.36
0.18
Interest Cover
33.05
25.90
71.12
317.29
76.33
33.13
19.40
21.81
7.39
47.20

News Update


  • USFDA completes pre-approval inspection at Biocon’s Malaysia facility
    21st Feb 2018, 09:03 AM

    The regulator has issued a Form 483 with 6 observations

    Read More
  • Biocon - Quarterly Results
    24th Jan 2018, 18:16 PM

    Read More
  • Biocon enters into business transfer agreement with BBIL
    24th Jan 2018, 09:25 AM

    The agreement is for transfer of its Biosimilars business to BBIL

    Read More
  • Biocon enters into partnership with Sandoz
    18th Jan 2018, 16:07 PM

    Both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products

    Read More
  • Biocon, Mylan’s Biosimilar Trastuzumab gets ANVISA’s approval
    29th Dec 2017, 11:44 AM

    This is the first biosimilar Trastuzumab to be approved in Brazil

    Read More
  • Biocon gets nod to transfer biosimilars business
    9th Dec 2017, 11:12 AM

    The special resolution was passed with 99.99 per cent of votes polled through postal ballot

    Read More
  • Biocon gets EMA regulator nod for proposed biosimilar trastuzumab, pegfilgrastim
    1st Dec 2017, 10:33 AM

    Pegfilgrastim is used to reduce the duration of neutropenia and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer

    Read More
  • Biocon launches KRABEVA for treating several types of cancer in India
    23rd Nov 2017, 10:52 AM

    KRABEVA will help expand access to a world class, high quality biosimilar Bevacizumab for cancer patients in India

    Read More
  • Biocon receives EIR from USFDA for aseptic drug product facility
    20th Nov 2017, 08:47 AM

    The USFDA has classified the outcome of this inspection as VAI and the EIR states that the inspection is closed

    Read More
  • Biocon’s arm extends partnership with Bristol-Myers Squibb till 2026
    14th Nov 2017, 12:08 PM

    The expanded scope of partnership also includes addition of a new facility and ramping up the team of scientists working for it

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.